

Title: Sustained SARS-CoV-2 seroprevalence and related hematological features in asymptomatic blood donors

Running Title: COVID-19 seroprevalence and hematimetry

Author names and affiliations:

M Carmen Martín ^a

M Isabel González ^a

Nuria Holgado ^a

Ana I Jimenez ^a

Nuria Ortega ^a

Isabel Page ^a

Alba Parrado ^a

María Pérez ^a

Lydia Blanco-Peris ^a

^a Centro de Hemoterapia y Hemodonación de Castilla y León, Paseo de Filipinos s/n, 47007 Valladolid, Spain

Corresponding author: M Carmen Martín; cmartinalo@saludcastillayleon.es; Centro de Hemoterapia y Hemodonación de Castilla y León, Paseo de Filipinos s/n, 47007 Valladolid, Spain

Sources of research support

This work has been supported by Roche Diagnostics International Ltd., who provided free equipment and test reagents. Roche Diagnostics International Ltd. was not involved, either in study design, collection, analysis and interpretation of data, the writing of the report or in the decision to submit the article for publication.

2 **Acknowledgements**

3 LB and MCM conceived and designed the study, NH, NO; MP and AP acquired data,
4 IP, AJ and MIGF performed analysis and interpretation of laboratory data, MCM and
5 LB drafted the article and revised it critically for important intellectual content, all
6 authors provided final approval of the version to be submitted.

7 The authors thank to all blood donors making this work possible by allowing
8 research use of their samples by the Biobanco del Centro de Hemoterapia y
9 Hemodonación de Castilla y León. They also thank the staff in charge of blood
10 donation, and lab technicians for their efforts and Roche for its support.

11 **Ethical considerations**

12 This study was conducted according with national regulations, institutional
13 policies and in the tenets of the Helsinki Declaration. This study was approved by
14 the Valladolid Health Area Drug Research Ethics Committee, in a meeting held
15 on June 11, 2020 with the reference number "BIO-2020-93". Included donors
16 consented to participate in Biobank research activities. The privacy rights of
17 human subjects were always observed.

Sustained SARS-CoV-2 seroprevalence and related hematological features in asymptomatic blood donors

18 **Abstract**

19 **Background and objectives:** COVID-19 can either cause death or go unnoticed
20 but antibodies will remain protecting us of SARS-CoV-2 reinfection for an
21 uncertain time and to a uncertain extent. Knowledge of COVID-19
22 epidemiological and hematological features should help make a good forecast of
23 resources for possible future outbreaks or vaccination strategies, and would
24 facilitate decisions in the social sphere by a more reliable estimate of the
25 percentage of immunized individuals. Our aim was to describe seroprevalence
26 evolution from summer 2019 to autumn 2020 in Spain and to determine its
27 relationship with age, blood group or haematological parameters.

28 **Materials and methods:** Sera and plasma from historical donation archives were
29 randomized and a total of 12,718 samples tested by a Chemiluminiscent analysis
30 for anti SARS-CoV-2 N protein total immunoglobulins. Blood donors were 60.9%
31 males, average age 46+/-13. Sex, age, blood group, blood cell counts and
32 percentages and immunoglobulin concentrations were extracted from electronic
33 recordings.

34 **Results:** 6.7% donors were positive by the end of 1st wave. No differences by
35 sex, age or blood group were found regarding antibodies. Leukocyte and
36 neutrophil counts were lower ($p<0.001$) and haemoglobin was lower ($p<0.001$) in
37 positive donations than in negative ones. Sex differences were found in
38 neutrophils, leukocytes, haemoglobin and haematocrit as related to SARS-CoV-2
39 antibodies.

40 **Conclusions:** Seroprevalence due to asymptomatic cases would be slightly
41 lower than the overall one due to age restrictions for blood donors. Sex and age

42 would not affect COVID-19 susceptibility but its severity. Gender differences
43 would be present in asymptomatic individuals. Further studies are needed to
44 confirm these gender differences as they can help better understand the immune
45 response to COVID-19, its pathogenesis and prognosis.

46

Keywords: COVID-19, antibodies, immunity, seroprevalence, SARS-CoV-2

47 **Abbreviations**

Immunoglobulin G (IgG); immunoglobulin A (IgA); immunoglobulin M (IgM);
polymerase chain reaction (PCR); standard deviation (SD); interquartile range
(IQR); White blood cells (WBC), haemoglobin (Hb), haematocrit (HCT), mean
corpuscular volume (MCV).

48 **Introduction**

49 Most SARS-CoV-2 infection cases develop an effective immune response during
50 infection. Even these who course asymptomatic or with just mild symptoms mount
51 humoral or cell responses. This makes it hard to calculate accurate infection or
52 fatality rates and prevalence [1]. Immunization either due to infection or to
53 vaccination leads to viral eradication and to specific T cell responses and
54 antibodies against SARS-CoV-2, that usually peak 8–15 days after infection [2].
55 Antibodies that neutralize the virus are the primary protection against COVID-19,
56 and lymphocyte responses augment protection.

57 Antibody assays are quite different: they either detect antibodies against different
58 viral proteins (S1, S1/S2, RBD or NC) or different immunoglobulin classes: IgG,
59 IgM, IgA or their combinations. It should be noticed that every approved vaccine
60 in Europe to date (May 2020) enhances anti-S responses, whereas an infection
61 leads to a multi specific response to SARS-CoV2 antigens. To make it even

62 messier, many factors can influence test performance, including cross-reactivity
63 with other coronaviruses or platform (laboratory-based vs point-of-care, lateral
64 flow). Chemiluminescence assays have suitable performances regarding both
65 sensibility and sensitivity while correlation to neutralizing antibodies would be
66 around 0.7 [3].

67 Our region, Castilla y Leon, with a population of 2.299.598 inhabitants, has
68 accumulated nearly 225.000 COVID-19 confirmed cases
69 (<https:// analisis.datosabiertos.jcyl.es/>), with an overall case-fatality rate of 3.01 to
70 date. Our institution, Centro de Hemoterapia de Castilla y León keeps within its
71 Biobank plasma samples from every single donation along the last ten years, that
72 makes up around one million samples. Any demographic data such as sex or age
73 and laboratory parameters (blood counts, blood group, haemoglobin, etc....) is as
74 well kept in a database (Hemasoft, eDelphyn).

75 Blood donor-based serosurveillance is a powerful and cost-effective strategy to
76 monitor infectious diseases. There are quite a lot of infections for which routine
77 donor screening is well known to be useful, including human immunodeficiency
78 virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), human T-
79 lymphotropic virus (HTLV), and West Nile virus (WNV) [1], babesiosis or
80 Crimea-Congo fever. The use of blood donor samples means we're sampling
81 mainly asymptomatic and recovered cases of COVID-19 (normal blood donation
82 is allowed after 28 days following COVID-19 symptoms' resolution).

83 Seroprevalence surveys are then needed to monitor coronavirus pandemic, both
84 before and after vaccination strategies [4]. Reported COVID-19 cases do not
85 represent the full SARS-CoV-2 disease burden due to low detection rates,
86 especially at the beginning of pandemics. Case reports are dependent on
87 patients' seeking health care, massive local screenings or regional tracking
88 activities. Analysis of data from seroprevalence and serosurveillance is a

89 common strategy for estimating underreporting and real disease burden. There
90 are several features that should be taken into account, including time between
91 infection and antibody development or antibody waning, which must be
92 considered to understand seroprevalence surveys avoiding biases. Any
93 seroprevalence survey should be evaluated for selection bias. Serological
94 surveys with a random sampling design of the general population are difficult to
95 perform in a pandemic, but a random sampling design of the general population
96 yields a seroprevalence estimate least likely to be affected by selection bias.
97 Blood donors are a quite representative subset of general population aged 18-65
98 and our historical plasma collection was big enough to perform a time-layered
99 randomization.

100 Heterogeneity of susceptibility and transmission is hard to evaluate but does exist
101 [5]. A portion of the population is not susceptible to infection from the first
102 pathogen contact. Some of them may have pre-existing immunity via cross-
103 reactivity or particular host factors such as mucosal immunity or trained innate
104 immunity protection (as it has been reported to be conferred by DTP or BCG
105 vaccination)[6]. There is as well a proportion of seronegative individuals that will
106 develop immunity by T cell mediated responses but without exhibiting an
107 antibody response [7].

108 The starting hypothesis is the existence of a certain number of asymptomatic
109 carriers of the SARS-CoV-2 virus that would develop antibodies against it [7] (and
110 subsequently contribute to herd immunity). Those asymptomatic cases were
111 unnoticeable before testing began and might had been circulating from an
112 unknown moment. Early cases have been described in France [8], arising the
113 question of whether the pathogen could have been circulating even before the
114 official recording of the first cases.-The main aim of this study was to determine
115 what percentage of the population has had contact with SARS-CoV-2 at different

116 times and has therefore developed antibodies against it. A secondary goal was to
117 describe haematological features of seropositive donors and establish whether
118 sex, age, blood group or haematological abnormalities were related COVID-19
119 exposure.

120 Knowledge of COVID-19 epidemiological and hematological features should help
121 make a good forecast of resources for possible future outbreaks or vaccination
122 strategies, and would facilitate decisions in the social sphere by a more reliable
123 estimate of the percentage of immunized individuals.

124 **MATERIAL and METHODS**

125 *Aim, design and setting of the study*

126 The aim of this study was to analytically obtain, a reliable knowledge of
127 asymptomatic COVID-19 cases and their immunological and haematological
128 characteristics, seroprevalence, rate of positive donations and its temporal
129 evolution along the first wave in Spain. So, a retrospective observational analysis
130 was performed.

131 *Participants*

132 The Biobank is included in the National Registry of Biobanks (RD17 / 16/2011)
133 with the number B.0000264. The institution holds an ISO 9001: 2015 certification
134 endorsing our granting of safety and traceability of any human biological sample
135 we distribute, always behaving Spanish and European rules on human samples
136 and data protection management.

137 The study population comprised randomised plasma-EDTA and serum frozen
138 samples from blood, plasma (excluding convalescent) and platelet donations
139 from July 2019 to October 2020. Donations collected since 19/07/2019 (week -
140 24) to 19/10/2020 (week 43) were randomized to select a minimum of 150

141 donations per week. A total of 12,718 samples of 11,444 donors over 18 years
142 old were included.

143 *Laboratory data and analyses*

144 All haematological and demographic data were extracted from electronic
145 database eDelphyn (Hemasoft). Variables analyzed included age, sex, blood
146 group, and laboratory data.

147 Major laboratory markers were extracted from our donation database. Routine
148 blood examinations included leukocyte (WBC), neutrophil, lymphocyte, platelet,
149 monocyte, eosinophil and basophil counts (cells*10³/μL) and their percentages.
150 Serum immunoglobulins IgG, IgA and IgM (mg/dL), haemoglobin (Hb),
151 haematocrit (HCT) and corpuscular mean volume were analysed as well.

152 An automated chemiluminiscence double-antigen sandwich immunoassay for the
153 in vitro semi quantitative detection of total antibodies to SARS-CoV-2 in human
154 serum and plasma was performed. The target antigen of this immunoassay is a
155 recombinant nucleocapsid (N) protein. Elecsys® Anti-SARS-CoV-2 (Roche,
156 Basel, Switzerland) detects antibodies correlating with virus-neutralizing ones
157 and is therefore useful to help characterize the immune reaction to SARS-CoV-2
158 [9, 10]. Immunoassay was validated by our serology lab by testing of 6 pairs of
159 samples (plasma EDTA and serum) from diagnosed PCR-positive, symptomatic
160 cases infected by mid-April, that were previously reported positive by the Spanish
161 National Microbiology Centre, and checked to be as well positive for IgG
162 (Chemiluminiscence, N protein, Abbott Alinity S, Chicago USA) and IgA (ELISA,
163 S protein, Euroimmun, Lübeck, Germany) antiSARS-CoV-2. Another set of ten
164 prepandemic samples, therefore supposed to be negative, were equally
165 analyzed. A 100% concordance was yielded by these validation assays. The cut-
166 off was that recommended by manufacturer (OD>1 to report reactivity).
167 Researchers performing anti SARS-CoV-2 analyses were blind to the condition of

168 COVID-19 convalescence and to any other characteristic of the donors or to the
169 donation dates.

170 *Statistical analysis*

171 Demographic and clinical characteristics of patients are expressed as their mean
172 and standard deviation (SD) for continuous variables and frequency distributions
173 are reported for categorical variables. Age was analysed both as continuous and
174 categorical variable; in the latter case was recoded into 4 groups: <30, 30-45, 45-
175 60, 60-75 years old.


176 Kolmogorov-Smirnov test was performed on each continuous variable to contrast
177 normality. Only IgG and IgM serum levels followed normal distributions, therefore
178 non-parametric Mann-Whitney U test was performed to compare laboratory
179 values. To contrast the hypothesis of independence within categorical variables,
180 Pearson's Chi-square and Fisher's exact test were carried out. All tests were
181 calculated with a confidence level of 0.05.

182 **Results**

183 A total of 12,718 randomized donations (either whole blood, plasmapheresis or
184 platelet apheresis) were tested for total anti SARS-CoV2 antibodies. Donors
185 made up 11,444, 60.91% males, aged 18-75, average 46+/-13, 45.8% A, 40.3%
186 O, 10.56% B, 3.31% AB.

187 Seropositivity rate grew up from week 11 to week 25, reaching a 11.1% peak,
188 with just subtle descents until week 43 when 2nd wave arose in our country.
189 Plateau was reached by the last week of May 2020, 11 weeks after close
190 lockdown in Spain (that begun in March, 15th) and 17 weeks after 31/01, the date
191 of the first declared case in our country. 660 out of 9,886 single donors were
192 positive within weeks 11 to 43, that makes a seroprevalence of 6.73% at the end
193 of the first wave.

194 Three 2019 donations were reactive (from July, September and October) but
 195 none of them were positive when testing separately IgG, IgA or IgM. Their ODs
 196 were 1.05, 1.08 and 5.46 respectively. 1,142 donations from year 2019 were
 197 analyzed.



198
 199 Figure 1. COVID-19 seropositive donation rate 2020 evolution by weeks. Temporal
 200 series' model (mobile median t=6; exponential smoothing model R[2]=0.991;p<0.001)
 201 No differences in anti SARS-CoV2 reactivity due to sex, age or blood group of
 202 donors were found (Table 1).

	Negative		Positive	
	n	%	n	%
Female	4531	38.1%	164	40.3%
Male	7375	61.9%	243	59.7%
<30	3551	29.8%	104	25.6%
30 to 45	5036	42.3%	180	44.2%
45 to 60	1151	9.7%	42	10.3%
60 to 75	2168	18.2%	81	19.9%
A	5411	45.5%	198	48.6%
AB	423	3.6%	16	3.9%
B	919	7.7%	22	5.4%
O	5151	43.3%	171	42.0%

203 Table 1. Sex, age range and blood group of positive/negative anti SARS-COV2 donations
 204 analysed

205 Immunoglobulin levels didn't show any differences as comparing positive and
206 negative donations. Haemoglobin (14.9 vs 14.7 g/dL; $p < 0.001$) and haematocrit
207 (45.2% vs 44.4%; $p < 0.001$) were both significantly lower in positive donations .
208 Leukocyte count (WBC) was as well slightly lower (7.23 vs 7.06 cells* $10^3/\mu\text{L}$;
209 $p = 0.026$) (Table 2). A trend was found of lower number of neutrophils (4.3 vs. 4.2
210 cells* $10^3/\mu\text{L}$; $p = 0.117$), lower count of monocytes (0.46 vs. 0.45 cells* $10^3/\mu\text{L}$;
211 $p = 0.117$) and higher percent of basophils (0.49% vs 0.51%; $p = 0.131$).

212 As layering data by sex (Table 3), the fact arose that haematocrit (46.8% vs
213 45.9%; $p < 0.001$) and haemoglobin (15.5 vs 15.3 g/dL; $p < 0.001$) were significantly
214 lower just in males and that positive females had significantly less WBC (7.67 vs
215 7.25 cells* $10^3/\mu\text{L}$; $p = 0.027$) and neutrophil numbers (4.53 vs 4.27
216 cells* $10^3/\mu\text{L}$; $p = 0.014$).

217 Some trends were found as well related to sex. Regarding positive women
218 neutrophil percent would be lower (59.4% vs 58.10% $p = 0.065$), with a higher
219 lymphocyte percent (31.7% vs 33.10%; $p = 0.074$) a lower platelet count (261 vs
220 255 cells* $10^3/\mu\text{L}$; $p = 0.152$), monocyte count (0.46 vs 0.44 cells* $10^3/\mu\text{L}$; $p = 0.132$)
221 and basophil percent (0.5% vs 0.4%; $p = 0.060$). Anaemia was more frequent in
222 positive male donors as (6.1% vs 9.6%; $p = 0.031$), A trend of. No other significant
223 differences were found either in males, females or overall. Figure 2 summarize
224 these findings.

	Overall	Male	Female
Hb	↓	↓	-
Hematocrite	↓	↓	-
Leukocyte count	↓	-	↓
Platelet count	-	-	↓
Neutrophil count	↓	-	↓
Neutrophil %	-	-	↑
Lymphocyte count	-	-	↓
Lymphocyte %	-	-	↓
Monocyte count	↓	-	↓
Basophil %	↑	-	↓

225

226 Figure 2. Haematological features in SARS-CoV-2 positive donations. Intense-
 227 coloured arrows represent significant differences. Light-coloured arrows
 228 represent statistical trends.

229 Discussion

230 A slightly lower seroprevalence than that found in general population was found
 231 among blood donors without COVID-19 antecedents. The 6.73% seroprevalence
 232 we found is a little lower than that reported in the seroprevalence study ENE-
 233 COVID-19 promoted by the *Instituto Nacional the Epidemiología* [11], where it is
 234 reported that a 7.2% of the participants in our region would have anti SARS-
 235 CoV2 IgG antibodies by the end of June 2020. Almost one quarter people in our
 236 region (25.51% according to National Institute of Statistics, INE 2020 data) is
 237 older than 65 and elderly are necessarily underrepresented in this study as it
 238 comprises blood donors. That happens as well with population aged less than 18
 239 (under 4.5% in our region). One limitation of this study is that of age, restricted to
 240 18-75 years old, but it would make just a little difference of 0.5% in
 241 seroprevalence estimation. Immunization rate would be a bit higher regarding the
 242 fact that some individuals do not exhibit antibodies but still mount an efficient
 243 specific T-cell response [2]

244 Perhaps the main strength of our study is the large number of samples we
245 randomized and tested along almost one year. The first recorded COVID-19 case
246 in Spain was reported on 31/01/2020, but 3 positive donations were found as
247 testing samples collected along 2019. That could be meaningful in two opposite
248 ways: one possible explanation would be cross reactivity to seasonal cold
249 coronaviruses and the other would be that SARS-CoV-2 might have been
250 circulating at least since 2019 summer.

251 It is now known that up to 28% people would have protection against SARS-CoV-
252 2 due to cross reaction to other coronaviruses [2]. It has been checked that long-
253 term cross-reactive both T-cell and antibodies can be a correlate of protections
254 against COVID-19 [12]. Asymptomatic or mild cases couldn't be diagnosed or
255 reported until the first tests were developed in the first term of 2020. There are
256 other reports about SARS-CoV-2 circulating in Europe along 2019. Italy's Ministry
257 of Health reported high levels of unusual strains of flu and pneumonia
258 concentrated in the area around Milan and appearing in 17 of Italy's 20 regions
259 [13]. Our three 2019 positive donors would be even earlier cases, but the
260 simplest explanation would be that of cross reaction. In fact, we cannot 100%
261 ascertain whether some of the positives along the period of study might be cross
262 reactions as well or both reactive due to SARS-CoV-2 infection together with
263 previous coronavirus immunity.

264 Conversely to clinical forms of COVID-19 [14,15] neither age nor sex have an
265 influence on the probability to develop an asymptomatic COVID-19 infection in
266 our cohort. Several smaller seroprevalence reports from European countries
267 support this feature [16-20]. It may be therefore ascertained that age and sex do
268 not have a role in SARSCoV-2 infection susceptibility, but only in their
269 progression to severe forms.

270 Blood group has been reported elsewhere [7,21-23] to confere susceptibility or
271 determine severity of SARS-CoV2 infection. Most studies do not separate
272 susceptibility and severity. It should be noticed that there are no large studies
273 characterizing asymptomatic cases in literature, perhaps this is one of the reports
274 comprising more asymptomatic individuals. Relationship of ABO system with
275 susceptibility is not supported by our data. We excluded convalescent plasma
276 donors, opposite to other studies, that focused into these asymptomatic positive
277 donors [22]. Perhaps blood group might be related only to symptomatic cases
278 and would be therefore related to severity but not related to asymptomatic SARS-
279 CoV-2 infection. Another surface antigens such as HLA or KIR might be as well
280 involved and should be studied.

281 Several blood count anomalies have been reported to be associated to SARS-
282 CoV2 infection, notably lymphopenia and neutrophilia are related to severest
283 forms [24]. Our data conversely reveal that asymptomatic positive women had a
284 significant lower count of WBC and neutrophils as compared to negative ones.
285 Similar low counts of WBC and neutrophils have been reported in young (<19)
286 cohorts, comprising mainly mild and asymptomatic cases [25]. Perhaps this
287 feature might be therefore a correlate of mildness. Elevation of monocytes have
288 been elsewhere reported in short series of mild cases [26]. Our observation in will
289 be in the same line of those findings but a gender bias cannot be discarded so far
290 seropositive women would go in the opposite direction.

291 Several reports about haemolytic anaemia secondary to SARSCoV-2 have been
292 published [27-30]. We cannot discard the possibility of a mild silent haemolytic
293 anaemia in asymptomatic cases. Again, little analysis of asymptomatic cases is
294 available by the moment.

295 We can conclude that seroprevalence estimations through blood donation
296 analysis resemble data obtained from population-based surveys. Sex and age

297 would not affect COVID-19 susceptibility but its severity. Gender differences are
298 present even in asymptomatic individuals: females are known to develop milder
299 COVID-19, this fact might be related to a lower WBC count whereas positive
300 males although asymptomatic, present anaemia more frequently than negative
301 ones. Further studies in large cohorts are needed to confirm these gender
302 differences and to characterize asymptomatic COVID-19 cases as they can help
303 better understand immune response to COVID-19, its pathogenesis and
304 prognosis.

305 **Availability of data and materials**

306 The data that support the findings of this study are not openly available due to reasons
307 of sensitivity and are available from the corresponding author upon reasonable request
308 and after mandatory approval of proposals by the Valladolid Este Ethical Committee

309

310

311 **References**

- 312 1. Busch MP, Stone M. Serosurveillance for Severe Acute Respiratory
313 Syndrome Coronavirus 2 (SARS-CoV-2) Incidence Using Global Blood
314 Donor Populations. *Clin Infect Dis*. 2020;72(2):254-256
- 315 2. Sekine T, Perez-Potti A, Rivera-Ballesteros O, Strålin K, Gorin JB, Olsson A,
316 et al. Robust T Cell Immunity in Convalescent Individuals with
317 Asymptomatic or Mild COVID-19. *Cell*. 2020 Oct 1;183(1):158-168.e14. doi:
318 10.1016/j.cell.2020.08.017. Epub 2020 Aug 14. PMID: 32979941; PMCID:
319 PMC7427556.
- 320 3. Wouters E, Steenhuis M, Schrezenmeier H, Tiberghien P, Harvala H, Feys
321 HB, van der Schoot E. Evaluation of SARS-CoV-2 antibody titers and
322 potency for convalescent plasma donation: a brief commentary. *Vox Sang*.
323 2021 May;116(5):493-496. doi: 10.1111/vox.13060. Epub 2020 Dec 23.
324 PMID: 33368373.
- 325 4. Angulo FJ, Finelli L, Swerdlow DL. Estimation of US SARS-CoV-2 Infections,
326 Symptomatic Infections, Hospitalizations, and Deaths Using
327 Seroprevalence Surveys. *JAMA Netw Open*. 2021;4(1):e2033706

- 328 5. Friston K, Costello A, Pillay D. 'Dark matter', second waves and
329 epidemiological modelling. *BMJ Glob Health*. 2020;5(12):e003978
- 330 6. Netea MG, van der Meer JW, van Crevel R. BCG vaccination in health care
331 providers and the protection against COVID-19. *J Clin Invest*.
332 2021;131(2):e145545
- 333 7. Gallais F, Velay A, Nazon C, Wendling MJ, Partisani M, Sibia J, Candon S,
334 Fafi-Kremer S. Intrafamilial Exposure to SARS-CoV-2 Associated with
335 Cellular Immune Response without Seroconversion, France. *Emerg Infect*
336 *Dis*. 2021;27(1):113–21
- 337 8. Gallian P, Pastorino B, Morel P, Chiaroni J, Ninove L, de Lamballerie X.
338 Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O
339 French blood donors. *Antiviral Res*. 2020;181:104880
- 340 9. Kohmer N, Westhaus S, Rühl C, Ciesek S, Rabenau HF. Brief clinical
341 evaluation of six high-throughput SARS-CoV-2 IgG antibody assays. *J Clin*
342 *Virol*. 2020;129:104480
- 343 10. Müller L, Ostermann PN, Walker A, et al. Sensitivity of anti-SARS-CoV-2
344 serological assays in a high-prevalence setting [published online ahead of
345 print, 2021 Feb 3]. *Eur J Clin Microbiol Infect Dis*. 2021;1-9
- 346 11. Pastor-Barriuso R, Pérez-Gómez B, Hernán MA, et al. Infection fatality risk
347 for SARS-CoV-2 in community dwelling population of Spain: nationwide
348 seroepidemiological study. *BMJ*. 2020;371:m4509
- 349 12. Poonia B, Kottlilil S. Immune Correlates of COVID-19 Control. *Front*
350 *Immunol*. 2020;11:569611
- 351 13. Murtas R, Decarli A, Russo AG. Trend of pneumonia diagnosis in
352 emergency departments as a COVID-19 surveillance system: a time series
353 study. *BMJ Open*. 2021;11(2):e044388.
- 354 14. Jurado A, Martín MC, Abad-Molina C, et al. COVID-19: age, Interleukin-6, C-
355 reactive protein, and lymphocytes as key clues from a multicentre retrospective
356 study. *Immun Ageing*. 2020;17:22
- 357 15. Martín MC, Jurado A, Abad-Molina C, Orduña A, Yarce O, Navas AM, et al. The
358 age again in the eye of the COVID-19 storm: evidence-based decision making.
359 *Immun Ageing*. 2021 May 20;18(1):24. doi: 10.1186/s12979-021-00237-w.
360 PMID: 34016150; PMCID: PMC8134808.
- 361
- 362 16. Dickson E, Palmateer NE, Murray J, et al. Enhanced surveillance of COVID-
363 19 in Scotland: population-based seroprevalence surveillance for SARS-
364 CoV-2 during the first wave of the epidemic. *Public Health*. 2021;190:132-
365 134
- 366 17. Hallal PC, Hartwig FP, Horta BL, et al. SARS-CoV-2 antibody prevalence in
367 Brazil: results from two successive nationwide serological household
368 surveys. *Lancet Glob Health*. 2020;8(11):e1390-e1398.

- 369 18. Bogogiannidou Z, Vontas A, Dadouli K, et al. Repeated leftover serosurvey
370 of SARS-CoV-2 IgG antibodies, Greece, March and April 2020. *Euro*
371 *Surveill.* 2020;25(31):2001369
- 372 19. Biggs HM, Harris JB, Breakwell L, et al. Estimated Community
373 Seroprevalence of SARS-CoV-2 Antibodies - Two Georgia Counties, April
374 28-May 3, 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(29):965-970
- 375 20. Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of anti-SARS-
376 CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a
377 population-based study. *Lancet.* 2020;396(10247):313-319
- 378 21. Pendu JL, Breiman A, Rocher J, Dion M, Ruvoën-Clouet N. ABO Blood
379 Types and COVID-19: Spurious, Anecdotal, or Truly Important
380 Relationships? A Reasoned Review of Available Data. *Viruses.*
381 2021;13(2):160
- 382 22. Muñoz-Díaz E, Llopis J, Parra R, et al. Relationship between the ABO blood
383 group and COVID-19 susceptibility, severity and mortality in two cohorts
384 of patients. *Blood Transfus.* 2021;19(1):54-63
- 385 23. Zalba Marcos S, Antelo ML, Galbete A, Etayo M, Ongay E, García-Erce JA.
386 Infection and thrombosis associated with COVID-19: Possible role of the ABO
387 blood group. *Infección y trombosis asociada a la COVID-19: posible papel del*
388 *grupo sanguíneo ABO. Med Clin (Barc).* 2020;155(8):340-343.
389 doi:10.1016/j.medcli.2020.06.020
- 390 24. Agbuduwe C, Basu S. Haematological manifestations of COVID-19: From
391 cytopenia to coagulopathy. *Eur J Haematol.* 2020;105(5):540-546
- 392 25. Toba N, Gupta S, Ali AY, ElSaban M, Khamis AH, Ho SB, Popatia R. COVID-19
393 under 19: A meta-analysis. *Pediatr Pulmonol.* 2021 Jun;56(6):1332-1341. doi:
394 10.1002/ppul.25312. Epub 2021 Feb 25. PMID: 33631060; PMCID: PMC8013606
- 395 26. Gatti A, Radrizzani D, Viganò P, Mazzone A, Brando B. Decrease of Non-Classical
396 and Intermediate Monocyte Subsets in Severe Acute SARS-CoV-2 Infection.
397 *Cytometry A.* 2020 Sep;97(9):887-890. doi: 10.1002/cyto.a.24188. Epub 2020
398 Aug 14. PMID: 32654350; PMCID: PMC7404377
- 399 27. Gruden G, Beggiato E, Camerino E, Capriotti S, Canepa S, Scandella M,
400 Avolio M, Pittalunga F, Barutta F, Durazzo M. Treatment with eltrombopag
401 of severe immune thrombocytopenia and hemolytic anemia associated
402 with COVID-19 pneumonia: a case report. *Ther Adv Hematol.* 2021 Apr
403 27;12:20406207211011353. doi: 10.1177/20406207211011353. PMID:
404 33995989; PMCID: PMC8082984.
- 405 28. Liput JR, Jordan K, Patadia R, Kander E. Warm Autoimmune Hemolytic
406 Anemia Associated With Asymptomatic SARS-CoV-2 Infection. *Cureus.*
407 2021 Mar 25;13(3):e14101. doi: 10.7759/cureus.14101. PMID: 33927918;
408 PMCID: PMC8075761.
- 409 29. Georgy JT, Jayakaran JAJ, Jacob AS, Gunasekaran K, Korula PJ, Devasia AJ,
410 Iyadurai R. Evans syndrome and immune thrombocytopenia in two
411 patients with COVID-19. *J Med Virol.* 2021 May;93(5):2642-2644. doi:

412 10.1002/jmv.26906. Epub 2021 Mar 9. PMID: 33634495; PMCID:
413 PMC8013600.

414 30. Mausoleo A, Henriquez S, Goujard C, Roque-Afonso AM, Noel N,
415 Lambotte O. Severe IgA-mediated autoimmune hemolytic anemia
416 triggered by SARS-CoV-2 infection. *Leuk Lymphoma*. 2021 Feb 22:1-5. doi:
417 10.1080/10428194.2021.1888378. Epub ahead of print. PMID: 33618609.

418 31. Goud PT, Bai D, Abu-Soud HM. A Multiple-Hit Hypothesis Involving
419 Reactive Oxygen Species and Myeloperoxidase Explains Clinical
420 Deterioration and Fatality in COVID-19. *Int J Biol Sci*. 2021 Jan 1;17(1):62-
421 72

422 32. Dattilo M. The role of host defences in Covid 19 and treatments
423 thereof. *Mol Med*. 2020;26(1):90

424

425

426 **Tables**

		n	mean	median	SD	IQR
Age	Negative	11906	44.0	45.8	12.8	34.2-54.2
	Positive	407	44.2	46.5	13.0	32.8-54.8
IgA	Negative	194	236.9	223.5	101.3	163-292
	Positive	5	224.4	274.0	92.3	134-282
IgG	Negative	194	1065.4	1037.5	217.4	910-1185
	Positive	5	1123.8	1095.0	249.9	924-1229
IgM	Negative	194	113.3	100.5	64.8	69-138
	Positive	5	103.0	89.0	41.7	78-97
WBC (p=0.026)	Negative	9759	7.4	7.2	1.8	6.13-8.49
	Positive	346	7.2	7.1	1.6	6.11-8.12
Hb (p<0.001)	Negative	11218	14.9	14.9	1.3	14-15.8
	Positive	386	14.7	14.7	1.2	13.8-15.4
Hematocrite (p<0.001)	Negative	11218	45.1	45.2	3.5	42.7-47.6
	Positive	386	44.5	44.4	3.5	42.3-46.6
Platelets	Negative	11217	247.9	243.0	54.3	211-280
	Positive	386	247.3	242.5	55.7	206-276
Neutrophil count (p=0.117)	Negative	11217	4.4	4.3	1.4	3.44-5.19
	Positive	386	4.3	4.2	1.2	3.34-5.03
Neutrophil %	Negative	11217	58.8	58.9	7.5	53.8-63.9
	Positive	386	58.5	58.7	7.1	54.3-63.4
Lymphocyte count	Negative	11216	2.3	2.3	0.7	1.86-2.72
	Positive	386	2.3	2.2	0.6	1.89-2.64
Lymphocyte %	Negative	11216	31.7	31.5	6.9	27-36.2
	Positive	386	32.1	32.4	6.6	27.3-36.1
Monocyte count (p=0.131)	Negative	11216	0.5	0.46	0.1	0.38-0.56
	Positive	386	0.5	0.46	0.1	0.37-0.54
Monocyte %	Negative	11216	6.5	6.4	1.5	5.5-7.4
	Positive	386	6.5	6.4	1.4	5.5-7.3
Eosinophil count	Negative	11217	0.2	0.2	0.1	0.09-0.23
	Positive	386	0.2	0.1	0.1	0.09-0.22
Eosinophil %	Negative	11217	2.5	2.1	1.8	1.3-3.2
	Positive	386	2.4	2.0	1.7	1.3-3.1
Basophil count	Negative	11217	0.0	0.0	0.0	0.02-0.04
	Positive	386	0.0	0.0	0.0	0.02-0.04
Basophil %	Negative	11217	0.5	0.5	0.2	0.3-0.6
	Positive	386	0.5	0.5	0.3	0.4-0.6

427 Table 2. Descriptive analysis of age, immunoglobulins (mg/dL), Hb(g/dL), hemogram
 428 counts (cells*10³/μL) and percentages of reactive and non-reactive donations

			n	mean	median	SD	IQR
Age	Female	Negative	4531	42.0	43.50	13.3	30.3-53.3
		Positive	164	42.1	45.39	13.6	28.6-53.1
	Male	Negative	7375	45.2	46.81	12.2	36.7-54.8
		Positive	243	45.7	46.98	12.5	35.5-55.9
IgA	Female	Negative	54	214.3	200.00	97.0	157-250
		Positive	3	235.3	274.00	105.5	116-316
	Male	Negative	140	245.6	233.50	101.9	176.5-302.5
		Positive	2	208.0	208.00	104.7	134-282
IgG	Female	Negative	54	1076.4	1062.50	191.3	964-1186
		Positive	3	1082.7	1095.00	152.9	924-1229
	Male	Negative	140	1061.2	1029.00	227.2	903-1181.5
		Positive	2	1185.5	1185.50	436.3	877-1494
IgM	Female	Negative	54	143.1	129.50	64.6	94-169
		Positive	3	114.3	89.00	53.7	78-176
	Male	Negative	140	101.8	90.00	61.3	64.5-121
		Positive	2	86.0	86.00	15.6	75-97
MCV	Female	Negative	3618	91.2	91.50	4.8	88.4-94.4
		Positive	142	91.2	91.40	4.1	88.9-93.5
	Male	Negative	6141	90.9	91.00	4.6	88.1-93.8
		Positive	204	90.6	91.00	4.8	88-94.1
WBC	Female*	Negative	3618	7.8	7.69	1.9	6.49-9
		Positive	142	7.4	7.21	1.5	6.27-8.26
	Male	Negative	6949	7.2	7.02	1.8	5.99-8.2
		Positive	229	7.1	6.98	1.6	6.01-8.03
Hb	Female	Negative	4269	13.8	13.80	0.9	13.2-14.4
		Positive	157	13.7	13.80	0.9	13.2-14.3
	Male*	Negative	6949	15.5	15.50	1.0	14.9-16.2
		Positive	229	15.3	15.30	1.0	14.7-15.8
HCT	Female	Negative	4269	42.4	42.30	2.7	40.6-44
		Positive	157	42.1	42.00	2.5	40.5-43.6
	Male*	Negative	6949	46.8	46.80	2.8	45-48.6
		Positive	229	46.2	45.90	3.0	44.3-47.7
PLT	Female	Negative	4268	265.9	261.00	56.6	228-300
		(t) Positive	157	261.0	255.00	60.5	219-296
	Male	Negative	6949	236.8	233.00	49.6	204-266
		Positive	229	237.9	234.00	50.2	203-266
Neutrophil count	Female*	Negative	4268	4.7	4.53	1.4	3.65-5.47
		Positive	157	4.4	4.27	1.2	3.56-5.08
	Male	Negative	6949	4.3	4.10	1.4	3.34-4.95
		Positive	229	4.2	4.10	1.2	3.24-4.97
Neutrophil %	Female	Negative	4268	59.2	59.40	7.4	54.2-64.3
		Positive	157	58.1	58.10	7.2	54-62.9
	Male	Negative	6949	58.6	58.70	7.5	53.6-63.6
		Positive	229	58.8	58.70	7.0	54.6-63.5

Lymphocyte count	Female*	Negative	4267	2.5	2.39	0.7	1.97-2.88
		Positive	157	2.4	2.35	0.6	2.02-2.81
	Male	Negative	6949	2.2	2.18	0.6	1.8-2.62
		Positive	229	2.2	2.17	0.6	1.8-2.51
Lymphocyte %	Female	Negative	4267	32.0	31.70	6.9	27.4-36.5
		(t) Positive	157	33.0	33.10	7.0	28.4-37
	Male	Negative	6949	31.5	31.30	6.9	26.8-36.1
		Positive	229	31.4	31.70	6.3	26.7-35.6
Monocyte count	Female	Negative	4267	0.5	0.46	0.1	0.37-0.55
		(t) Positive	157	0.5	0.44	0.1	0.36-0.52
	Male	Negative	6949	0.5	0.46	0.1	0.38-0.56
		Positive	229	0.5	0.47	0.1	0.38-0.55
Monocyte %	Female	Negative	4267	6.1	6.00	1.4	5.1-6.9
		Positive	157	6.1	6.00	1.4	5.2-6.9
	Male	Negative	6949	6.7	6.60	1.5	5.7-7.6
		Positive	229	6.7	6.70	1.4	5.8-7.6
Eosinophil count	Female	Negative	4268	0.2	0.14	0.1	0.09-0.21
		Positive	157	0.2	0.13	0.1	0.09-0.19
	Male	Negative	6949	0.2	0.16	0.1	0.1-0.24
		Positive	229	0.2	0.15	0.1	0.09-0.23
Eosinophil %	Female	Negative	4268	2.2	1.80	1.6	1.2-2.8
		Positive	157	2.3	1.80	1.7	1.1-2.8
	Male	Negative	6949	2.7	2.20	1.8	1.4-3.4
		Positive	229	2.5	2.10	1.7	1.4-3.2
Basophil count	Female	Negative	4268	0.0	0.03	0.0	0.02-0.05
		Positive	157	0.0	0.04	0.0	0.02-0.05
	Male	Negative	6949	0.0	0.03	0.0	0.02-0.04
		Positive	229	0.0	0.03	0.0	0.02-0.04
Basophil %	Female	Negative	4268	0.5	0.40	0.2	0.3-0.6
		(t) Positive	157	0.5	0.50	0.3	0.3-0.6
	Male	Negative	6949	0.5	0.50	0.2	0.3-0.6
		Positive	229	0.5	0.50	0.2	0.4-0.6

430 *p<0.01

431 (t) p<0.2

432 Table 3. Descriptive analysis of age, immunoglobulins (mg/dL), Hb(g/dL), MCV,
 433 hemogram counts (cells*10³/μL) and percents, of reactive and non-reactive donations
 434 by sex.

435

436